Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases by Avram, A et al.
Disponible en ligne sur
www.sciencedirect.com
Defi ning a Role for Canakinumab 
and IL-1 inhibition in Diffi cult-to-Treat 
Gouty Arthritis
October 2015
Vol. 82 – e-Supplement 1
p. eS1-eS32
ISSN 1297-319X
85
31
8
Joint Bone Spine
S
up
pl
em
en
t
Joint	Bone	Spine	82	(2015)	eS17-eS29
*Corresponding	author.
E-mail address:	w.schmidt@immanuel.de	(W.A.	Schmidt).
©	2015	Société	française	de	rhumatologie.	Published	by	Elsevier	Masson	SAS.	All	rights	reserved.
Article	produced	with	the	institutional	support	of	Novartis.
Identifying	Patient	Candidates	for	IL-1	Inhibition:	
Lessons	From	Real-World	Cases
Annalina	Avrama,	Cátia	Duarteb,	Maria	José	Santosc,	Charalampos	Papagorasd,	Konstantinos	
Ritise,	Roberto	Scarpionif,	Wolfgang	A.	Schmidtg,	Panagiotis	Skendrosh
aMedical Doctor; Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin – Buch, Berlin, Germany 
bRheumatologist, Rheumatology Department, Centro Hospitalar, Universitario de Coimbra, Coimbra, Portugal 
cMedical Doctor, Department of Rheumatology, Hospital Garcia de ‘Orta, Lisbon, Portugal 
University Hospital of Alexandroupolis, Alexandroupolis, Greece 
dRheumatologist, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, 
University Hospital of Alexandroupolis, Alexandroupolis, Greece 
eProfessor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, 
University Hospital of Alexandroupolis, Alexandroupolis, Greece 
fHead, Department of Nephrology and Dialysis, Ospedale AUSL “Guglielmo da Saliceto”, Piacenza, Italy 
gDeputy Director, Immanuel Krankenhause Berline Medical Centre for Rheumatology Berlin - Buch, Berlin, Germany 
hAssistant Professor of Internal Medicine, First Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, 
University Hospital of Alexandroupolis, Alexandroupolis, Greece
A B S T R A C T
A	subgroup	of	patients	with	gouty	arthritis	have	a	chronic	recurring	form	that	is	particularly	diffi	cult	
to	treat.	Such	patients	experience	repeated	fl	ares	and	often	have	abundant	tophi.	Many	also	have	
underlying	comorbidities,	such	as	renal	impairment,	cardiovascular	disease,	gastrointestinal	disorders,	
obesity,	and	hypertension,	which	contraindicate	the	use	of	standard	anti-infl	ammatory	medications.	
Five	patients	with	diffi	cult	to	treat	gouty	arthritis	who	were	either	candidates	and/or	treated	with	
anti-IL	therapy	are	described.	
©	2015	Société	française	de	rhumatologie.	Published	by	Elsevier	Masson	SAS.	All	rights	reserved.
Keywords:
Anakinra
Anti−IL-1β	therapy
Canakinumab
Gouty	arthritis
Tophaceous	gout
1.	 IL-1	Inhibition	in	Systemic	Infl	ammatory	
Syndrome	Due	to	Gouty	Arthritis
1.1. Introduction
In	addition	to	the	rising	prevalence	of	polyarticular	involve-
ment	in	gouty	arthritis,	an	increasing	number	of	patients	with	
severe	systemic	infl	ammatory	syndrome	due	to	gouty	arthritis	
are	being	admitted	to	hospitals.	However,	 few	reports	have	
been	published	on	this	condition	[1].	Here	we	present	one	of	
several	such	cases	admitted	to	our	hospital	department	for	acute	
rheumatology	and	clinical	immunology.
1.2. Case Report
A	68-year-old	man	was	admitted	at	night	on	October	2,	2013	
from	an	emergency	unit	of	another	hospital	to	the	Medical	Centre	
for	Rheumatology	Berlin-Buch	with	undefi	ned	infl	ammation	
and	polyarthritis.	He	had	had	low-grade	fever	with	chills	and	
night	sweats	for	2	weeks,	and	his	overall	health	condition	was	
severely	impaired.	He	had	lost	5	kg	within	the	past	8	weeks	and	
was	unable	to	rise	and	walk.	Five	days	before	admission,	he	had	
received	clindamycin	due	to	suspected	erysipelas	of	the	lower	
legs,	resulting	in	an	allergic	rash.	Deep	vein	thrombosis	was	
excluded	by	ultrasound.	
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Since	1985,	the	patient	has	had	a	history	of	gout	attacks	
with	typical	podagra	and	had	been	taking	a	daily	dose	of	100	mg	
allopurinol.	He	also	took	colchicine	on	demand	when	experien-
cing	a	gout	attack.	Over	the	past	year,	he	developed	multiple	
visible	tophi.	Previous	uric	acid	levels	were	not	available.	He	
consumed	approximately	1	liter	of	beer	per	day.	In	addition,	the	
patient	was	treated	with	amlodipine	and	ramipril	for	arterial	
hypertension,	and	with	gabapentin	for	epilepsy.	Renal	colic	
has	not	been	noted.
On	physical	examination,	the	patient	appeared	severely	ill	
with	multiple	joint	swellings	and	tophi,	particularly	of	both	first	
metatarsophalangeal	(MTP)	joints,	ankle	joints,	knee	joints,	third	
right	proximal	interphalangeal	(PIP)	joint,	first	and	second	left	
metacarpophalangeal	(MCP)	joints,	and	elbows	(Fig.	1).	Both	first	
MTP	joints,	the	third	right	PIP	joint,	the	first	left	MCP	joint,	and	
both	knees	were	particularly	reddened	and	hot.	The	patient	was	
176	cm	tall	and	weighed	73	kg.
Laboratory	findings	at	admission	were	as	follows:	C-reactive	
protein	(CRP)	level	=	267	mg/L;	erythrocyte	sedimentation	rate	=	
125	mm/h;	uric	acid	level	=	8.1	mg/dL	(480	μmol/L);	and	serum	
creatinine	=	normal,	with	an	estimated	glomerular	filtration	
rate	=	78	mL/min.	
Radiography	showed	typical	erosions	and	tophi	at	the	both	
first	MTP	joints	as	well	as	at	the	first	left	MCP	joint.	Ultrasound	
of	the	knees	and	the	first	toes	showed	typical	features	of	gout,	ie,	
tophi,	aggregates,	double	contour	sign,	and	erosions	(Fig.	2)	[2,3].	
Double	contour	was	detected	in	both	first	MTP	joints	and	at	
the	inter-condylar	femoral	region	of	both	knees.	Tophi	were	
noted	in	both	first	MTP	joints	and	at	both	quadriceps	and	patel-
lar	tendons.	Ultrasound	also	revealed	bilateral	kidney	stones.	
Ultrasound	guided	aspiration	of	the	left	first	MTP	joint	revealed	
2	mL	of	dense	white	fluid.	Multiple	urate	crystals	could	be	seen	
by	polarizing	light	microscopy	in	the	aspirate.	Gram	stain	and	
bacterial	culture	were	negative.	
The	patient	received	daily	colchicine	1.5	mg	throughout	hos-
pitalization.	Because	his	symptoms	did	not	improve,	daily	oral	
prednisolone	50	mg	was	added,	followed	by	daily	intravenous	
prednisolone	70	mg.	His	symptoms	and	CRP	values	(Fig.	3)	did	not	
significantly	improve.	Blood	and	aspirate	cultures	were	negative.	
Subsequently	(from	October	16−22),	the	patient	received	daily	
subcutaneous	(sc)	anakinra	100	mg.	His	systemic	symptoms,	
pain,	and	joint	redness	improved	the	day	after	the	first	injection.	
His	CRP	level	dropped	to	28	mg/L	on	October	20.	Treatment	with	
febuxostat	120	mg/day	was	initiated	on	October	22.	The	patient	
Figure	1.	Acute	polyarticular	tophaceous	gout	with	A)	red	swollen	MTP	1	joints;	B)	bilateral	prepatellar	tophi;	C)	inflamed	right	PIP	
3	joint;	and	D)	inflamed	left	MCP	joint	with	deformity.
MCP,	metacarpophalangeal;	MTP,	metatarsophalangeal;	PIP,	proximal	interphalangeal.	
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was	informed	about	dietary	issues	and	stopped	drinking	beer.	On	
October	23,	following	final	negative	results	for	bacterial	cultures	
and	tuberculin	tests,	he	received	sc	canakinumab	150	mg.	
The	patient	remained	well	and	had	no	adverse	effects	from	
the	newly	 initiated	medications.	Prednisolone	was	 tapered.	
No	colchicine	was	given.	On	November	26,	his	CRP	level	was	
12	mg/L	and	uric	acid	level	was	5.5	mg/dL	(330	μmol/L).	On	
December	7,	he	had	a	gout	attack	of	a	first	MTP	joint	for	which	
he	took	colchicine	1.5	mg.	His	symptoms	resolved	the	next	day	
and	he	remained	on	daily	colchicine	1	mg.	
On	January	16,	2014,	the	patient	visited	the	office	to	ascertain	
as	to	whether	another	canakinumab	injection	would	be	indicated	
following	the	12	weeks	that	passed	since	the	first	injection	was	
administered.	 Since	 colchicine	 had	 been	 reinitiated,	 he	 had	
no	additional	gout	attacks.	Painless	tophi	and	joint	swellings	
without	redness	were	still	present.	His	CRP	level	was	2	mg/L	and	
uric	acid	level	was	5.5	mg/dL	(326	μmol/L).	Treatment	with	col-
chicine	1	mg/day	and	febuxostat	120	mg/day	was	continued,	and	
the	patient	did	not	receive	additional	canakinumab	injections.
In	 April	 2014,	 the	 patient	 had	 1	 minor	 gout	 attack	 of	 a	
first	MTP	joint.	On	April	28,	his	CRP	level	was	8	mg/L	and	uric	
acid	 level	was	4.5	mg/dL	(272	μmol/L).	Treatment	remained	
unchanged.	No	further	gout	attacks	occurred	until	July	24	when	
his	CRP	level	was	2	mg/L	and	his	uric	acid	level	was	3.5	mg/dL	
(213	μmol/L).	The	febuxostat	dose	was	subsequently	reduced	to	
80	mg/day.	The	patient	regained	the	weight	he	had	lost	during	
the	acute	phase	of	the	disease	and	remained	at	a	weight	of	78	kg	
throughout	the	time	of	observation.	
Until	 January	 2015,	 the	 patient	 was	 taking	 prophylaxis	
colchicine	0.5	mg/day	(reduced	from	1	mg/day	since	October	
2014)	and	reported	no	further	gout	attacks.	Joint	swelling	and	
tophi	significantly	decreased.	His	CRP	levels	remained	normal	
and	his	uric	acid	levels	remained	<5.0	mg/dL	(300	μmol/L).	
1.3. Discussion
Systemic	 inflammatory	 syndrome	 due	 to	 gouty	 arthritis	
appears	to	be	under	reported	in	the	literature.	These	patients	are	
often	unsuccessfully	treated	for	suspected	infection.	Many	of	them	
improve	with	colchicine	or	glucocorticoid	therapy.	However,	some	
patients,	as	the	one	we	report	on,	are	resistant	to	such	treatment.	
Interleukin-1	(IL-1)	inhibition	is	an	option	for	these	patients.	
Rilonacept,	 canakinumab,	 and	 anakinra	 have	 been	 used	
successfully	in	the	treatment	of	patients	with	gouty	arthritis.	In	
randomized,	controlled	trials,	both	rilonacept	and	canakinumab	
have	been	shown	to	prevent	flares	in	patients	initiating	urate-
lowering	therapy	(ULT)	[4,5].	However,	only	canakinumab	has	
consistently	shown	in	phase	III	trials	to	be	effective	treatment	for	
acute	flares	and	to	reduce	the	risk	of	new	flares	in	patients	with	
difficult-to-treat	disease	[6].	Anakinra	has	shown	benefit	in	the	
treatment	of	patients	with	acute	and	chronic	gouty	arthritis	in	
pilot	studies,	retrospective	reviews,	and	case	reports	[7].
Canakinumab	is	the	only	anti−IL-1	inhibitor	approved	for	
gouty	 arthritis.	 In	 2013,	 canakinumab	 was	 approved	 in	 the	
European	Union	for	the	treatment	of	patients	with	frequent	
gouty	arthritis	attacks	(≥3	attacks	in	the	previous	12	months)	
in	whom	NSAIDs	and	colchicine	are	contraindicated,	are	not	
tolerated,	or	do	not	provide	an	adequate	response,	and	in	whom	
repeated	courses	of	corticosteroids	are	not	appropriate	[8].	
After	failure	of	NSAIDs,	colchicine,	and	prednisolone	treat-
ment,	we	started	our	patient	on	anti-IL	therapy	with	anakinra	
Figure	2.	Ultrasound	image	of	 the	right	MTP	1	 joint	showing	
multiple	tophi	(*)	and	double	contour	sign	(**).
MTP,	metatarsophalangeal.
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Figure	3.	Medication	and	CRP	levels	at	the	acute	phase	of	the	disease.
CRP,	C-reactive	protein.
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(off-label	use),	which	has	a	relatively	short	half-life,	to	determine	
if	IL-1	inhibition	would	be	effective	for	our	patient	and	to	rule	
out	acute	bacterial	infection	and	chronic	tuberculosis.	We	then	
administered	1	injection	of	canakinumab	in	an	outpatient	setting	
to	continue	the	anti-inflammatory	effect.	Although	febuxostat	
treatment	was	initially	started	with	the	higher	approved	dose	
of	120	mg/day	to	reduce	the	urate	 load	as	soon	as	possible,	
paradoxical	flares	did	not	occur	in	the	first	weeks	of	ULT.	
In	patients	who	respond	to	canakinumab	and	require	retreat-
ment,	there	should	be	an	interval	of	at	least	12	weeks	before	
a	new	dose	of	canakinumab	can	be	administered	on	demand	
during	an	attack	[8].	In	our	patient,	colchicine	prophylaxis	was	
sufficient	for	preventing	major	gout	attacks	and	systemic	inflam-
matory	syndrome	over	the	course	of	time.	Of	note,	canakinumab	
is	not	approved	for	flare	prophylaxis,	rather	only	for	treatment	
of	acute	flares.	
In	conclusion,	inflammatory	syndrome	due	to	gouty	arthritis	
indeed	exists,	and	additional	case	reports	or	case	series	need	to	be	
published.	IL-1	inhibition	appears	to	be	effective	for	the	condition.
2.	 Anti−IL-1	Therapy	Suppresses	Inflammation		
and	Provides	an	Opportunity	to	Optimize	ULT		
in	a	Patient	with	Difficult-to-Treat	Gouty	
Arthritis
2.1. Introduction
Gouty	arthritis,	the	most	common	inflammatory	arthritis	
worldwide,	 is	 caused	 by	 chronic	 hyperuricemia	 and	 tissue	
deposition	of	monosodium	urate	crystals	(MSU).	The	condition	
occurs	predominantly	in	men	and	older	women.	Its	prevalence	
has	been	increasing	in	developed	counties,	with	approximately	
1	in	40	adults	in	the	United	Kingdom	being	affected	[9].	Acute	
arthritis	is	the	most	common	feature	leading	to	diagnosis.	If	the	
hyperuricemia	is	not	adequately	treated	at	the	stage	of	intermit-
tent	acute	flares,	gout	can	progress	to	a	chronic	and	destructive	
polyarthritis,	which	can	mimic	rheumatoid	arthritis	(RA).
The	human	and	economic	burden	of	gouty	arthritis	is	high	
and	continues	to	rise	with	the	aging	of	the	population,	increasing	
rates	of	obesity,	and	lifestyle	changes	[10].	Many	patients	with	
gouty	arthritis	have	comorbidities,	either	at	diagnosis	or	during	
the	course	of	the	disease	[11].	Cardiovascular,	renal,	and	meta-
bolic	disorders	most	commonly	coexist	in	patients	with	gouty	
arthritis.	Additionally,	malignancies,	gastrointestinal	disorders,	
and	other	diseases	are	overrepresented	in	these	patients	[11].	
The	management	of	patients	with	gouty	arthritis	is	often	
suboptimal,	particularly	in	patients	with	multiple	comorbidities,	
who	are	particularly	difficult-to-treat	[9,12].	We	present	a	patient	
with	chronic	tophaceous	gout	who	has	multiple	comorbidities,	
limiting	the	use	of	standard	therapies.
2.2. Case Report
A	48-year-old	Caucasian	man	was	referred	to	the	outpatient	
rheumatology	clinic	with	suspected	RA.	He	reported	that	since	
the	age	of	35,	he	has	had	painful	joint	symptoms,	which	initially	
were	localized	to	the	lower	limbs	but	more	recently	involved	
the	hands,	wrists,	and	elbows.	 Initially,	his	symptoms	were	
episodic,	 subsided	 spontaneously,	 and	 did	 not	 significantly	
interfere	with	his	daily	activities.	Within	the	following	years,	
the	painful	episodes	gradually	became	longer	in	duration	and	
currently,	the	pain	is	almost	constant.	He	noticed	the	appearance	
of	slightly	painful	subcutaneous	(sc)	nodules	on	his	fingers	and	
elbows,	progressive	deformation	of	his	fingers,	and	limitation	
of	his	wrist,	ankle,	and	knee	movements	that	interfered	with	
his	daily	activities.
The	patient	previously	worked	as	a	policeman,	performing	
mostly	administrative	duties.	He	had	been	consuming	0.5	liter	
of	wine	and	1	to	2	beers	daily.	He	has	a	history	of	hypertension	
that	was	controlled	with	 lisinopril	and	hydrochlorothiazide	
20/12.5	mg/day.	For	several	years,	he	used	over-the-counter	
nonsteroidal	anti-inflammatory	drugs	(NSAIDs)	to	control	joint	
pain.	Because	NSAIDs	were	no	longer	providing	sufficient	pain	
relief,	he	recently	sought	medical	care.	After	consulting	his	gene-
ral	practitioner,	he	was	diagnosed	with	symmetric	deforming	
polyarthritis	and	was	started	on	prednisolone	10	mg/day.	His	
family	history	was	unremarkable.
On	physical	examination,	the	patient	had	a	mild	limping	gait.	
His	blood	pressure	was	163/98	mm	Hg,	heart	rate	was	72	bpm,	
and	body	mass	index	was	31	kg/m2.	Multiple	firm	nontender	sc	
nodules	were	present	on	both	elbows	and	dorsum	of	the	fingers.	
Ulcerated	nodules	on	the	pulps	of	his	left	thumb	and	third	to	
fifth	fingers	were	also	present	(Fig.	4).	The	range	of	motion	of	
his	shoulders,	elbows,	knees,	ankles,	and	subtalar	joints	was	
limited,	and	his	knees,	wrists,	metacarpophalangeal	(MCP)	joints	
and	some	proximal	interphalangeal	(PIP)	joints	were	tender	and	
swollen.	The	remainder	of	his	physical	examination	was	normal.
X-ray	films	of	the	patient’s	hands	and	feet	showed	multiple	
joint	deformities	and	extensive	bony	erosions	of	the	wrist,	and	
MCP,	PIP,	(Fig.	5),	and	metatarsophalangeal	joints.	The	com-
plete	blood	count	was	normal,	as	were	blood	levels	of	alanine	
aminotransferase,	albumin,	globulin,	and	alkaline	phosphatase.	
Other	test	results	are	shown	in	Table	1.	The	estimated	glomerular	
filtration	rate	was	49	mL/min.	
A	diagnostic	arthrocentesis	of	his	knee	was	performed	and	
analysis	of	the	synovial	fluid	showed	a	cell	count	of	37,000	cells/
mm3,	predominantly	polymorphonuclears;	Gram	staining	was	
negative.	Numerous	MSU	crystals	were	identified	under	pola-
rized	light	microscopy.	Aspiration	of	1	sc	nodule	also	revealed	the	
presence	of	MSU	crystals.	The	diagnosis	of	chronic	tophaceous	
gout	was	established,	and	treatment	goals	included	symptomatic	
control	of	polyarthritis,	reduction	of	uricemia,	and	prevention	
of	further	attacks.	
Considering	the	patient’s	comorbidities	(metabolic,	cardio-
vascular,	and	renal	disorders),	NSAIDs	were	discontinued	and	
low-dose	colchicine	was	prescribed	(0.5	mg/day).	To	control	
his	hypertension,	losartan	100	mg/day	was	substituted	for	lisi-
nopril/hydrochlorothiazide.	Urate-lowering	therapy	(ULT)	with	
allopurinol	50	mg/day	was	started,	and	tapering/discontinuation	
of	glucocorticoids	was	planned	as	soon	as	satisfactory	pain	relief	
could	be	achieved.	Lifestyle	changes	were	strongly	encouraged,	
namely	 stopping	 regular	 alcohol	 intake	 and	 reducing	 body	
weight.	
The	patient	continued	to	have	persistent	pain	in	his	knees	
and	ankles	that	severely	limited	walking.	In	addition,	he	conti-
nued	to	experience	frequent	flares	that	prevented	optimal	ULT	
dosing.	After	4	months	of	treatment,	elevated	uricemia	persisted,	
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polyarticular	gouty	attacks	continued,	and	treatment	adherence	
was	poor.	At	this	point,	interleukin	(IL)-1	inhibition	was	conside-
red,	and	the	patient	consented	to	a	trial	of	anakinra	100	mg/day	
sc	(the	only	IL-1	antagonist	commercially	available	at	that	time	
in	Portugal	[approved	for	the	indication	of	moderate	to	severe	
rheumatoid	arthritis]).	Anakinra	led	to	a	rapid	and	complete	
resolution	of	symptoms,	permitting	the	tapering	and	eventual	
discontinuation	of	steroids,	and	a	gradual	dose	increase	of	ULT.	
Anakinra	was	initially	administered	for	1	week	and	on	demand	
thereafter	(for	2−3	days	to	abrogate	gouty	flares).	One	year	later,	
the	patient	was	clear	of	arthritis,	his	 serum	urate	 level	was	
controlled,	and	his	renal	function	remained	stable.	He	continues	
to	have	moderate	pain	in	his	ankle	and	foot	after	exercising	that	
can	be	managed	without	the	use	of	analgesics.	He	also	continues	
to	have	limitation	of	movement	of	his	shoulders,	elbows,	fingers,	
and	subtalar	joints	but	is	able	to	continue	to	work.
Figure	4.	Patient’s	left	hand	with	finger	tophi	and	ulcerations	of	digital	pulps.
Figure	5.	Hand	radiographs	show	destructive	arthropathies	of	the	wrist	and	MCP	joints
MCP,	metacarpophalangeal.
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2.3. Discussion
This	case	illustrates	the	potential	management	challenges	in	
patients	with	gouty	arthritis	who	have	multiple	comorbidities.	
The	therapeutic	goals	for	gouty	arthritis	are	control	of	acute	
arthritis,	prevention	of	future	attacks,	and	control	of	comor-
bidities.	In	the	present	case,	a	long	period	of	time	had	elapsed	
between	the	patient’s	initial	symptoms	and	diagnosis,	and	for	
many	years,	 the	patient	had	used	NASIDs	regularly	without	
appropriate	monitoring.	
Gastrointestinal,	cardiovascular,	and	renal	side	effects	are	
associated	with	chronic	NSAID	use	[13],	and	although	NSAIDs	
constitute	the	first	line	of	treatment	for	acute	gouty	arthritis,	
their	use	is	not	recommended	when	renal	function	is	impai-
red	[14].	Likewise,	the	use	of	corticosteroids	is	not	the	most	
appropriate	treatment	given	the	risk	of	worsening	the	metabolic	
control	and	aggravating	cardiovascular	risk.	Colchicine	may	be	
an	alternative	 for	patients	who	cannot	 tolerate	NSAIDs,	but	
the	dosage	should	be	reduced	in	patients	with	renal	failure.	
Colchicine	can	be	useful	for	controlling	acute	attacks	as	well	as	
for	preventing	flares	when	initiating	ULT.	Unfortunately,	this	was	
not	the	case	in	our	patient,	who	continued	to	experience	gouty	
flares	despite	taking	colchicine	and	prednisolone,	especially	
when	trying	to	increase	the	allopurinol	dose.
Patients	with	gouty	arthritis	and	multiple	coexisting	comor-
bidities	have	limited	treatment	options	and	can	be	particularly	
challenging	to	treat.	Recently,	IL-1	inhibition	has	been	shown	to	
be	effective	for	controlling	acute	arthritis	in	patients	intolerant	
or	refractory	to	conventional	therapies	[6,15].	Canakinumab	has	
been	approved	in	the	European	Union	for	patients	with	frequent	
gouty	arthritis	attacks	who	cannot	be	managed	with	standard-
of-care	medication.	However,	it	was	not	available	in	Portugal	at	
the	time	our	patient	was	being	treated.	Anakinra,	which	proved	
effective,	was	the	only	available	IL-1	inhibitor.
A	few	case	reports	in	the	literature	document	the	efficacy	of	
ankinra	in	acute	gout	but	its	use	remains	off-label	[15].	In	the	
present	case,	IL-1	inhibition	was	crucial	to	abrogate	inflamma-
tion	and	allow	the	successful	introduction	of	effective	doses	of	
allopurinol	and	the	discontinuation	of	steroids.	Additionally,	
this	therapeutic	approach	contributed	to	the	patient’s	improved	
self-confidence	and	adherence	to	treatment.	The	most	challen-
ging	aspect	of	the	treatment	plan	is	the	long-term	adherence	to	
urate	lowering	drugs	and	implementation	of	lifestyle	changes,	
including	healthy	eating,	eliminating	alcohol	beverages,	and	
weight	control,	which	are	crucial	not	only	for	gout	control	but	
especially	for	reducing	cardiovascular	disease	risk.
In	summary,	gouty	arthritis	management	should	address	
the	patient	as	a	whole	and	take	into	account	the	presence	of	
comorbidities.	IL-1	inhibition	represents	a	significant	advance	
in	the	treatment	of	patients	with	limited	therapeutic	options.
3.	 Treatment	Dilemma	in	Gouty	Arthritis:	
Managing	a	Patient	With	Complex	Comorbidities	
and	Intolerance	to	Standard	Therapies
3.1. Introduction
Gouty	arthritis	 is	an	ancient	disease.	Despite	 significant	
advances	in	the	understanding	of	its	risk	factors,	etiology,	patho-
genesis,	prevention,	and	treatment,	millions	of	people	diagnosed	
with	gout	have	repeated	attacks	of	acute	arthritis	and	other	
complications.	Comorbid	conditions,	that	often	accompany	gout,	
present	challenges	when	managing	the	condition	[16].	
3.2. Case Report
A	70-year-old	man	with	tophaceous	gout	and	a	20-year	history	
of	gouty	arthritis	was	referred	to	our	rheumatology	outpatient	
clinic.	He	reported	a	history	of	recurrent	acute	monoarthritis	
involving	 his	 first	 metatarsophalangeal	 joint.	 Eventually,	 he	
developed	more	severe	joint	involvement,	with	polyarthritis,	
shorter	inter-critical	periods,	and	tophus	development	(Fig.	6).	He	
now	experiences	frequent	polyarthritis	attacks	(2−3	per	month).
Over	the	years,	the	patient	developed	multiple	comorbidities	
including	type	2	diabetes	mellitus,	hypertension,	dyslipidaemia,	
chronic	kidney	disease	(glomerular	filtration	rate,	50	mL/min),	
and	 upper	 gastrointestinal	 (GI)	 bleeding	 and	 a	 peptic	 ulcer	
associated	with	NSAID	overuse.	Five	years	ago,	he	was	diagnosed	
with	monoclonal	gammapathy	of	undetermined	significance	
(MGUS),	and	in	2012,	he	had	an	acute	myocardial	infarction.
Initially,	the	patient	achieved	a	good	clinical	response	with	the	
use	of	nonsteroidal	anti-inflammatory	drugs	(NSAIDs)	or	colchicine.	
However,	due	to	the	development	peptic	ulcer	disease	and	a	high	
risk	of	cardiovascular	disease	(history	of	an	acute	event),	NSAIDs	
were	subsequently	contraindicated.	He	also	developed	GI	intole-
rance	(diarrhoea)	to	colchicine	when	the	dose	used	was	greater	than	
1	mg/day.	Low-dose	colchicine	was	not	effective	in	controlling	his	
acute	episodes.	To	control	the	frequent	severe	attacks,	the	patient	
was	prescribed	glucocorticoid	(GC)	therapy	(30	mg/day)	with	dose	
tapering	(30,	20,	10,	5	mg/day)	every	3	days	until	discontinuation.	
GC	therapy	resulted	in	uncontrolled	hyperglycaemia,	but	this	was	
the	only	available	treatment	option	for	our	patient.	
Allopurinol	(100	mg/day),	in	conjunction	with	prophylactic	
colchicine	(0,5	mg/day),	was	also	initiated.	However,	the	patient	
developed	a	severe	hypersensitivity	with	intense	pruritus	and	
skin	lesions.	Despite	undergoing	a	desensitization	program	with	
antihistamine	treatment,	he	was	unable	to	tolerate	a	dose	greater	
than	12.5	mg/day	of	allopurinol.	No	other	urate-lowering	therapy	
(ULT)	is	available	in	Portugal.
Despite	making	lifestyle	changes	(low-purine	diet,	no	alcohol	
consumption,	good	hydration,	and	weight	loss),	taking	vitamin	C	
Table	1
Laboratory	Results
ESR 36	mm/h N	<	16	mm/h
Fasting	blood	glucose 158	mg/dL N	<	110	mg/dL
Serum	creatinine 2.4	mg/dL N	<	0.9	mg/dL
Serum	uric	acid 11.7	mg/dL N	<	6.8	mg/dL
IgM	RF Negative
ACPA Negative
ACPA,	anti-citrullinated	protein	antibodies;	ESR,	erythrocyte	sedimentation	rate;	
IgM,	immunoglobulin	M;	N,	normal;	RF,	rheumatoid	factor.	
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supplements,	receiving	medications	associated	with	uricosuric	
properties	(losartan	50	mg/day	and	fenofibrate	267	mg/day)	
to	control	comorbidities,	and	avoiding	hyperuricemic	drugs	
(diuretic	agents	and	low-dose	aspirin),	the	patient’s	acid	uric	
levels	remain	persistently	elevated	(12.1	mg/dl).
3.3. Discussion
Herein	we	report	on	a	patient	with	complicated	gouty	arth-
ritis	who	remains	untreated	due	to	limited	treatment	options	
because	of	his	multiple	comorbidities.	Choosing	appropriate	
treatment	strategies	for	these	types	of	patients	deserves	further	
discussion.	
Based	on	treatment	guidelines/recommendations	for	gouty	
arthritis	[14,	17-19],	colchicine	and	NSAIDs	are	first-line	treat-
ment	options	for	acute	gout	attacks.	In	2	randomized	clinical	
trials	[20,21],	colchicine	was	shown	to	be	superior	compared	
with	placebo	in	the	treatment	of	acute	gout.	In	one	of	those	trials,	
early	 self-administered	 low-dose	 (1.8	 mg/1	 hour)	 colchicine	
yielded	efficacy	in	gout	flare	management	comparable	with	that	
of	high-dose	(4.8	mg/6	hours)	colchicine,	with	a	safety	profile	
indistinguishable	from	that	of	placebo	[21].	Several	trials	compa-
ring	various	NSAID	agents	in	the	management	of	gouty	arthritis	
found	no	significant	differences	in	efficacy	among	the	agents	[17].	
The	choice	between	colchicine	and	NSAIDs	is	driven	by	patient´s	
preference	and/or	contraindications	to	a	specific	agent.	In	patients	
with	severe	gouty	arthritis,	the	American	College	of	Rheumatology	
(ACR)	guidelines	recommend	NSAIDs	in	combination	with	colchi-
cine	[19].	In	our	patient,	traditional	NSAIDs	were	contraindicated	
due	to	a	history	of	GI	bleeding.	COX-2	inhibitors	were	avoided	due	
to	the	patient’s	high	cardiovascular	risk.	
For	 patients	 with	 an	 acute	 severe	 gout	 attack,	 the	 ACR	
guidelines	recommend	corticosteroids	alone	or	in	combination	
with	colchicine	[19].	The	route	of	administration	depends	on	
the	number	and	type	of	joints	involved.	Oral	corticosteroids	are	
recommended	for	polyarticular	involvement,	and	intra-articular	
corticosteroids	are	recommended	when	1	to	2	large	joints	are	
involved	[19].	Due	to	the	severe	polyarticular	involvement	in	
our	patient,	we	prescribed	a	short	course	of	a	medium-to-high	
dose	of	prednisone	(30	mg/day,	with	tapering)	that	provided	
good	control	of	his	symptoms	but	negatively	impacted	control	
of	his	diabetes.	
New	alternative	treatments	are	now	available	for	patients	
with	severe	gouty	arthritis	refractory	to	other	agents.	Biologic	
IL-1	inhibitors	agents,	such	as	canakinumab	(approved	in	the	
European	Union),	can	be	considered.	In	a	phase	III,	randomized,	
controlled	trial	 (RCT),	canakinumab	150	mg	provided	signi-
ficantly	greater	and	more	rapid	reduction	 in	pain	and	signs	
and	symptoms	of	inflammation	compared	with	triamcinolone	
acetonide	40	mg.	Improvement	in	health-related	quality	of	life	
occurred	in	both	treatment	groups	but	with	a	faster	onset	with	
canakinumab	150	mg	compared	with	triamcinolone	acetonide	
40	mg	[22],	confirming	the	results	of	a	phase	II	dose-finding,	RCT,	
in	which	canakinumab	150	mg	provided	rapid	and	sustained	
pain	relief	in	patients	with	acute	gouty	arthritis,	and	significantly	
reduced	the	risk	of	recurrent	flares	compared	with	triamcinolone	
acetonide	[23].	
Given	our	patient’s	severe	acute	gout	attacks	and	his	limited	
treatment	options	due	to	comorbidities,	canakinumab	may	be	
a	promising	alternative	to	standard	therapy.	Because	patients	
with	MGUS	have	a	risk	of	progression	to	multiple	myeloma	or	
related	malignancy,	we	must	carefully	weigh	the	benefits	versus	
the	risks	of	canakinumab	use.	At	this	time,	no	safety	data	exists	
for	the	use	of	canakinumab	in	patients	with	MGUS	and	other	
plasma	cell	neoplasms.
Another	important	component	in	the	management	of	patients	
with	gouty	arthritis	is	the	use	of	chronic	ULT.	Xanthine	inhibi-
tors,	such	as	allopurinol	or	febuxostat,	are	considered	first-line	
ULT	[14,17,18,24].	Taking	into	consideration	the	efficacy,	safety,	
and	costs	of	allopurinol,	there	is	a	strong	consensus	in	using	it	
as	the	first	option	[17].	Low-to-medium	doses	(80	or	120	mg/
day)	of	 febuxostat	can	be	considered	 in	patients	who	do	not	
respond	or	are	contraindicated	to	allopurinol.	Uricosuric	agents,	
such	as	probenecid	or	benzobromarone,	can	be	considered	when	
xanthine-oxidase	inhibitors	do	not	achieve	adequate	control.	
Pegloticase	is	efficacious	but	is	associated	with	an	increased	risk	
of	acute	attacks	and	infusion	reactions,	and	its	use	should	be	consi-
dered	carefully	[17,25].	Our	patient	had	a	severe	hypersensitivity	
Figure	6.	Tophi	in	the	patient’s	hand	and	foot	
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reaction	to	allopurinol.	Febuxostat	and	uricosuric	agents	are	not	
available	in	our	country	(Portugal).	Upon	special	request	to	our	
regulatory	authority,	we	were	granted	access	to	febuxostat.	The	
patient	received	febuxostat	80	mg	day;	his	last	uric	acid	level	
decreased	to	6.2	mg/dL	and	he	has	had	no	new	acute	attacks.	
Although	gouty	arthritis	is	a	common	disease	and	efficacious	
treatment	is	available	for	most	patients,	this	case	illustrates	the	
challenges	in	managing	the	condition	in	patients	with	complex	
comorbidities	and	limited	treatment	options.
4.	 Managing	a	Patient	With	Persistent	Gout	
Flares	Complicated	by	Comorbidities	and	
Polypharmacy:	An	Evidence-based	Approach
4.1. Introduction
Gouty	 arthritis	 is	 a	 common	 type	 of	 arthritis	 that	 affects	
approximately	2%	of	 the	adult	population.	 Interleukin-1β	 (IL-
1β)−mediated	 inflammation	that	 is	 triggered	by	monosodium	
urate	 (MSU)	crystals	 is	 the	hallmark	of	 the	pathogenesis	of	a	
gout	attack	[26,27].	Recently,	both	the	European	League	Against	
Rheumatism	(EULAR)	and	the	American	College	of	Rheumatology	
(ACR)	published	guidelines	and	recommendations	for	the	mana-
gement	of	gout	[19,24,28].	However,	in	daily	practice,	physicians	
often	fail	to	effectively	treat	their	patients,	and	patients	fail	to	
comply	with	their	prescribed	treatment	–	both	contributing	factors	
as	to	why	some	patients	remain	exposed	to	the	long-term	toxic	
consequences	of	accumulating	urate	crystals	in	joints,	soft	tissues,	
and	elsewhere	[29,30].	Moreover,	patients	with	gouty	arthritis	often	
have	multiple	comorbidities,	limiting	the	use	of	anti-inflammatory	
and	urate-lowering	drugs	due	to	potential	adverse	drug	reactions	
and	interactions.	Herein,	we	discuss	the	management	of	a	real-life	
patient	with	recurrent	gouty	arthritis	and	multiple	comorbidities.
4.2. Case Report
A	76-year-old	Caucasian	man	presented	to	the	outpatient	
office	complaining	of	pain	and	swelling	of	his	left	wrist	over	
the	past	few	days.	During	the	preceding	year	he	had	had	several	
bouts	of	acute	arthritis	(left	ankle,	right	ankle,	right	knee),	all	of	
which	had	been	treated	with	paracetamol	and	topical	application	
of	ice.	The	resolution	of	each	arthritis	attack	was	slow	and	partial,	
and	was	shortly	followed	by	a	new	attack.
The	patient	had	multiple	significant	comorbidities.	He	was	
obese	with	a	body	mass	index	of	39.8	kg/m2,	and	he	had	chronic	
obstructive	pulmonary	disease	(COPD)	due	to	past	smoking,	
and	sleep	apnea	syndrome.	He	also	had	arterial	hypertension,	
type	2	diabetes	mellitus,	ischemic	heart	disease,	chronic	atrial	
fibrillation,	and	congestive	heart	failure.	He	was	on	fosinopril,	
amlodipine,	hydrochlorothiazide,	furosemide,	digoxin,	dabiga-
tran,	glibenclamide,	sitagliptin,	and	montelukast.
On	physical	evaluation,	the	patient’s	blood	pressure	was	
140/70	mm	Hg,	temperature	was	36.7	oC,	and	weight	was	254	
pounds	(115	kg).	He	had	acute	arthritis	of	the	left	wrist	but	no	
detectable	tophi.	Irregular	heart	tones	and	a	significant	bilateral	
lower	limb	edema	were	noted.	
Laboratory	tests	revealed	an	unremarkable	blood	count	and	
raised	inflammatory	markers	(erythrocyte	sedimentation	rate,	
30	mm/h;	C-reactive	protein,	15	mg/L).	The	serum	biochemistry	
panel	 revealed	elevated	 levels	of	glucose	 (187	mg/dL),	urea	
(92	mg/dL),	creatinine	(1.14	mg/dL),	urate	(11.5	mg/dL),	and	
mild	hyponatremia	(serum	sodium,	132	mEq/L);	serum	liver	
enzymes	and	creatine	phosphokinase	activities	were	within	
normal	ranges.	Serum	lipid	levels	were	also	within	target	for	the	
patient’s	profile	(cholesterol,	155	mg/dL;	triglycerides,	87	mg/
dL;	high-density	lipoprotein	cholesterol,	28	mg/dL).	
Musculoskeletal	ultrasound	of	the	affected	wrist	showed	
at	least	grade	2	gray	scale	and	power	Doppler	synovitis,	both	
indicative	of	active	arthritis.	On	joint	aspiration,	a	small	amount	
of	synovial	fluid	was	retrieved,	showing	an	increased	leukocyte	
count	(2400/mm3),	consisting	mainly	of	neutrophils	(58%)	and	
scattered	needle-shaped	crystals.
The	 patient	 was	 diagnosed	 with	 recurrent	 acute	 gouty	
arthritis	and	was	prescribed	oral	methylprednisolone	(8	mg	
daily	for	5	days	followed	by	tapering	and	discontinuation	over	
the	next	10	days)	and	colchicine	0.5	mg	tid.	Long-term	febuxostat	
80	mg	daily	was	also	prescribed,	which	was	to	begin	after	the	
attack	subsided,	along	with	maintenance	colchicine	for	at	least	
3	months	to	prevent	further	attacks.	Dietary	measures	were	
also	recommended.	A	few	days	later,	the	patient	reported	an	
improvement	of	his	arthritis.	However,	his	blood	glucose	level	
had	risen	>200	mg/dL	and	he	was	having	bouts	of	diarrhea.	The	
patient	was	advised	to	reduce	the	colchicine	dosage	to	0.5	mg	
bid.	Soon	after,	the	gouty	attack	resolved	fully;	the	patient	started	
febuxostat	while	remaining	on	low-dose	colchicine.	However,	
2	weeks	later	he	experienced	acute	arthritis	of	the	left	ankle	and	
received	a	new	course	of	oral	glucocorticoids	while	remaining	on	
the	same	regimen	of	febuxostat	and	colchicine.	Ten	days	after	the	
resolution	of	the	attack,	another	attack	occurred	at	the	third	left	
metacarpophalangeal	joint.	Repeat	serum	biochemistry	showed	
the	patient’s	serum	urate	level	had	decreased	to	8.51	mg/dL	but	
was	not	yet	optimal	(<6	mg/dL).	Therefore,	it	became	apparent	
that	the	patient’s	therapeutic	regimen	needed	to	be	modified.	
What	are	the	most	appropriate	steps	to	take	at	this	time?
4.3. Discussion
This	case	illustrates	the	potential	management	challenges	
for	 some	patients	with	gouty	arthritis	 referred	 to	a	 tertiary	
care	 hospital,	 particularly	 by	 general	 practitioners	 or	 other	
specialists,	 as	 these	 patients	 have	 the	 most	 severe	 disease	
and/or	major	comorbidities.	Evidence	shows	that	at	the	time	
of	diagnosis,	patients	with	gouty	arthritis	have	a	significantly	
higher	 prevalence	 of	 comorbid	 conditions	 compared	 with	
matched	non-gout	controls,	as	well	as	a	higher	 incidence	of	
new	comorbidities	after	the	diagnosis	of	gout.	In	addition	to	the	
spectrum	of	metabolic	syndrome	comorbidities,	these	patients	
have	a	broad	range	of	cardiovascular,	genitourinary,	endocrine,	
and	other	disorders.	Furthermore,	patients	with	gouty	arthritis	
have	a	slightly	increased	mortality	risk	even	after	adjusting	for	
baseline	comorbidities	and	other	confounding	factors	[11].
Treatment	for	gouty	arthritis	consists	of	addressing	3	aspects:	
1)	changing	lifestyle	factors	that	increase	serum	urate;	2)	anti-
inflammatory	treatment	for	the	management	and	prevention	of	
acute	arthritis;	and	3)	urate-lowering	therapy	(ULT)	[19,24,28].	
The	patient	presented	herein	had	significant	cardiopulmo-
nary	disorders	that	make	lifestyle	changes	challenging.	COPD	and	
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congestive	heart	failure	limit	the	ability	for	physical	exercise	and	
weight	loss,	whereas	severe	peripheral	edema	makes	it	difficult	
to	reduce	diuretics.
With	 regard	 to	 anti-inflammatory	 treatment,	 of	 the	
3	first-line	available	options	(nonsteroidal	anti-inflammatory	
drugs	[NSAIDs],	colchicine,	glucocorticoids),	NSAIDs	are	the	least	
attractive	option	for	this	patient,	as	they	can	impair	the	renal	
function	of	an	already	mildly	dehydrated	patient,	 leading	to	
water	retention,	hypertension,	and	heart	failure	decompensa-
tion.	They	can	also	increase	the	risk	for	gastrointestinal	bleeding,	
particularly	in	elderly	patients	with	chronic	hypoxia	receiving	
anticoagulants.	Finally,	even	if	the	newest	cyclooxygenase-2	
selective	NSAIDs	are	considered,	the	risk	for	acute	cardiovascular	
events,	which	is	high	in	elderly	men	with	type	2	diabetes	and	
ischemic	heart	disease,	does	not	make	them	a	safer	option.
Low-dose	colchicine	is	primarily	recommended	for	long-
term	prophylaxis	against	new	flares	and	may	be	advantageous	
over	NSAIDs	for	this	purpose	[18,19].	It	is	also	recommended	for	
the	treatment	of	recent	onset	(<36	hours)	acute	arthritis	[31],	
even	without	the	need	for	high	and	usually	intolerable	doses	
recommended	in	the	past	[18].	Furthermore,	in	a	clinical	trial	
involving	patients	with	stable	coronary	artery	disease,	the	addi-
tion	of	colchicine	(0.5	mg/day)	to	standard	therapy	improved	
cardiovascular	outcomes.	Although	these	findings	need	to	be	
replicated	in	patients	with	gouty	arthritis,	these	results	may	
offer	another	advantage	of	low-dose	colchicine	prophylaxis	in	
patients	with	gouty	arthritis	[31].
A	short	course	of	oral	glucocorticoids	may	also	be	useful	for	
the	resolution	of	an	acute	attack	and	can	be	co-administered	
safely	with	colchicine.	However,	the	known	long-term	toxicity	
of	glucocorticoids	limits	their	use	for	prophylaxis	[19,28].	In	our	
patient,	the	initial	colchicine/methylprednisolone	combination	
for	the	treatment	of	acute	attack	was	favored,	because	it	was	felt	
that	low-dose	colchicine	alone	could	not	achieve	remission	in	
a	patient	who	was	overweight	and	whose	gout	flare	had	been	
ongoing	for	several	days.	
ULT	should	begin	at	or	soon	after	anti-inflammatory	prophy-
laxis	initiation.	The	target	serum	urate	level	should	be	<6	mg/
dL	or,	in	severe	disease,	<5	mg/dL	[24,28].	An	xanthine	oxidase	
inhibitor	(ie,	allopurinol,	febuxostat)	is	the	first-line	drug	class	
for	ULT.	The	ACR	recommendations	do	not	favor	either	agent	
over	the	other	[24];	however,	the	recent	EULAR	recommen-
dations	advocate	the	use	of	allopurinol	as	first	line	in	patients	
with	normal	renal	function	[28].	When	prescribing	allopurinol,	
particularly	to	patients	with	renal	impairment,	caution	should	
be	 taken	 in	choosing	 the	starting	dose	and	subsequently	 in	
raising	it,	to	avoid	hypersensitivity;	however,	this	has	recently	
been	debated	[28,32].	As	for	the	allopurinol	versus	febuxostat	
comparison,	in	a	meta-analysis,	febuxostat	was	more	effective	in	
achieving	the	<6mg/dL	urate	target	level	compared	with	allopu-
rinol.	However,	this	difference	did	not	result	in	a	similar	benefit	
in	the	incidence	of	gout	flares.	Febuxostat	was	associated	with	
a	slightly,	but	significantly,	lower	incidence	of	adverse	events	
compared	with	allopurinol	[33].
Because	our	patient	had	a	very	high	baseline	serum	urate	
level,	febuxostat	was	chosen	based	on	data	from	a	phase	III	trial	
in	which	36%	of	patients	with	baseline	serum	urate	levels	≥10	
mg/dL	who	received	febuxostat	achieved	a	serum	urate	level	
<6	mg/dL	in	the	final	3	monthly	measurements,	compared	with	
only	10%	of	patients	who	received	allopurinol	[34].	Additionally,	
febuxostat	was	expected	to	act	faster	than	allopurinol,	because	
there	is	no	need	to	start	at	low	doses	and	titrate	up,	as	is	sugges-
ted	with	allopurinol.	In	our	patient,	almost	1	month	of	febuxostat	
80	mg	daily	lowered	serum	urate	by	3	mg/dL.	However,	this	
swift	decline	may	have	triggered	the	subsequent	arthritis	attacks	
despite	the	concomitant	low-dose	colchicine.	This	appears	to	
have	also	occurred	during	the	aforementioned	trial	in	which	
withdrawals	due	to	gout	flares	were	more	common	in	febuxos-
tat-	than	in	allopurinol-treated	patients	[34].
Independently	of	whether	the	new	attacks	are	the	result	of	
an	abrupt	decline	of	serum	urate	or	the	still	elevated	urate	levels,	
it	is	the	anti-inflammatory	treatment	that	clearly	failed	in	the	
case	described.	Therefore,	an	alternative	treatment	option	should	
be	considered	for	patients	with	frequent	gouty	arthritis	attacks	
who	are	not	being	successfully	managed	with	standard-of-care	
medication.	
The	recognition	that	IL-1β	plays	a	key	role	in	the	pathogenesis	
of	MSU-induced	inflammation	led	to	the	trials	of	IL-1β	inhibition	
in	patients	with	gouty	arthritis,	offering	an	alternative	therapy	
in	the	difficult-to-treat	patient.	To	date,	3	anti−IL-1	biologic	
agents	have	been	evaluated	in	patients	with	gouty	arthritis,	
either	in	small,	open-label,	retrospective	studies,	such	as	the	IL-1	
receptor	antagonist	anakinra	[7,35]	or	in	randomized,	controlled	
trials,	such	as	the	IL-1	trap	rilonacept	[5,36]	and	the	anti−IL-1β	
monoclonal	antibody	canakinumab	[6].	Today,	only	canakinu-
mab	is	approved	in	the	European	Union	for	the	treatment	of	
adult	patients	with	frequent	gouty	arthritis	attacks	(at	least	3	
in	the	previous	12	months)	in	whom	NSAIDs	and	colchicine	are	
contraindicated,	are	not	tolerated,	or	do	not	provide	an	adequate	
response,	and	in	whom	repeated	courses	of	corticosteroids	are	
not	appropriate.	
Canakinumab	has	been	studied	in	patients	with	gouty	arth-
ritis	who	have	multiple	comorbidities	and	failure,	intolerance	
or	contraindication	to	NSAIDs	and/or	colchicine	in	2	phase	III	
studies.	In	these	3-month	clinical	trials	with	12-week	extensions,	
canakinumab	150	mg	proved	more	effective	than	triamcinolone	
40	mg	for	the	treatment	of	acute	gout	and	the	prevention	of	
new	gout	flares.	However,	adverse	events	were	 reported	 in	
66%	of	canakinumab-treated	patients	compared	with	53%	in	
triamcinolone-treated	patients	over	24	weeks;	most	were	mild	
or	moderate.	Adverse	events	reported	more	frequently	with	
canakinumab	included	infections,	 low	neutrophil	count,	and	
low	platelet	count	[6].
The	next	important	step	in	the	management	plan	for	the	case	
presented	herein	is	a	discussion	with	the	patient	to	assess	the	
severity	of	symptoms	and	to	balance	the	benefits	versus	risks	
of	the	addition	of	anti-cytokine	therapy	versus	the	on-demand	
use	of	short	courses	of	glucocorticoids,	until	the	serum	urate	
target	level	of	<6	mg/dL	is	achieved.	The	target	serum	urate	level	
should	be	aggressively	pursued	and	may	require	frequent	serum	
urate	level	measurements	and	optimization	of	ULT,	by	increasing	
the	febuxostat	dose	and	potentially	adding	a	uricosuric	agent.	
Whichever	 anti-inflammatory	 treatment	 is	 selected,	 only	 a	
sustained	decrease	of	serum	urate	to	optimal	levels	will	keep	
the	patient	symptom-free	in	the	long	term	and	prevent	tophus	
formation.	Furthermore,	in	patients	with	difficult-to-treat	gouty	
arthritis	associated	with	major	comorbidities,	the	importance	
of	an	interdisciplinary	approach	cannot	be	over	emphasized.	
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5.	 An	Innovative	Approach	to	Managing	a	Patient	
With	Complicated	Gouty	Arthritis	and	Chronic	
Kidney	Disease
5.1. Introduction
The	 incidence	 of	 chronic	 kidney	 disease	 (CKD)	 is	 rising	
rapidly	worldwide,	resulting	in	significant	clinical,	economic,	
and	social	costs	[37].	Hyperuricemia	is	increasingly	recognized	
as	a	risk	factor	for	renal	failure	progression.	Moreover,	increased	
serum	uric	acid	levels	may	be	linked	to	cardiovascular	disease	
and	mortality	in	patients	with	CKD	[38].	
Gouty	arthritis,	a	painful	and	potentially	disabling	form	of	arth-
ritis,	is	caused	by	the	overproduction	of	urate	or,	more	commonly,	
by	renal	urate	underexcretion.	The	condition	leads	to	monosodium	
urate	crystals	deposition	 in	the	 joints	caused	by	 longstanding	
hyperuricemia.	Gouty	arthritis	is	generally	characterized	by	intense	
episodes	of	painful	swelling	in	single	joints,	most	often	in	the	big	toe,	
that	appear	red	and	warm	[39].	Tissue	deposition	of	urate	crystals	
in	the	interstitial	space	of	the	kidneys	can	also	lead	to	renal	failure	
as	a	result	of	supersaturation	of	extracellular	fluids	with	urate	[40].
5.2. Case Report
A	74-year-old	man	was	admitted	to	our	hospital	with	persis-
tent	diarrhea,	vomiting,	and	reduction	of	urine	output	(despite	
taking	furosemide	75	mg/day).	He	also	reported	arthralgias	with	
recurrent	attacks	of	pain,	particularly	in	his	hand	joints,	and	a	
persistent	left	lumbar	colic	pain.	
Thirty	 years	 ago,	 the	 patient	 was	 diagnosed	 with	 type	 2	
diabetes	and	hypertension,	which	was	currently	being	treated	
with	an	angiotensin-converting	enzyme	inhibitor	(ACE-I)	and	
β-blockers	(ramipril	5	mg/day;	metoprolol	50	mg/day).	He	had	a	
cardiologic	history	of	aortic	valvular	stenosis	and	coronary	artery	
disease	with	unstable	angina.	Two	months	before	presentation,	he	
was	diagnosed	with	non-Q-wave	myocardial	infarction,	without	
undergoing	coronary	angiography	due	to	several	comorbidities.	
The	patient	also	has	stage	3	CKD,	and	4	years	before	had	an	episode	
of	acute	kidney	injury	(AKI)	with	anuria	that	required	2	hemodia-
lysis	treatments.	He	also	had	a	history	of	gouty	arthritis	and	had	
been	self-medicating	with	nonsteroidal	anti-inflammatory	drugs	
(NSAIDs)	for	4	years	to	manage	his	symptoms.
On	admission,	the	patient’s	blood	pressure	was	110/70	mm	Hg,	
he	appeared	dehydrated,	and	reported	losing	almost	9	pounds	(4	
kg)	during	the	past	week.	Upon	physical	examination,	tophaceous	
gout	lesions	at	his	metacarpophalangeal	joints	were	noted.
Results	of	the	patient’s	 laboratory	tests	were	as	follows:	
serum	creatinine	=	1.68	mg/dL,	with	an	estimated	glomerular	
filtration	rate	of	39	mL/min	(calculated	by	the	Chronic	Kidney	
Disease	Epidemiology	Collaboration	formula);	albuminuria	=	
680	mg/day;	serum	potassium	=	3.2	mEq/L;	serum	bicarbonate	
(HCO3)	=	18	mmol/L;	serum	uric	acid	=	10.8	mg/dL;	C-reactive	
protein	 (CRP)	=	8.5	mg/dL;	blood	glucose	=	174	mg/dL;	and	
glycosylated	hemoglobin	=	8.4%.	Renal	ultrasound	examination	
showed	bilateral	renal	stones	(on	the	left	more	than	the	right	
side)	with	left	renal	hydronephrosis;	renal	cortical	thickness	
was	within	normal	limits.
Current	treatment	options	to	control	pain	and	inflammation	
of	acute	and	chronic	gouty	arthritis	include	NSAIDs,	colchicine,	
and	corticosteroids	(Table	2).	However,	NSAIDs	should	not	be	
used	in	patients	with	acute	kidney	injury	[40],	and	colchicine	
therapy	 is	 associated	 with	 significant	 side	 effects,	 namely	
gastrointestinal	(GI)	side	effects.	Despite	presenting	with	GI	
symptoms	on	admission,	our	patient	was	initially	treated	with	
low-dose	allopurinol	and	colchicine.	After	2	days,	allopurinol	was	
stopped	due	to	hypersensitivity	characterized	by	leukocytoclas-
tic	vasculitis	with	cutaneous	raised	palpable	petechiae.	Of	note,	
diuretics	and	amoxicillin	(added	to	our	patient’s	regimen	due	to	a	
concomitant	urinary	tract	infection)	are	believed	to	increase	the	
risk	of	hypersensitivity	to	allopurinol.	Additionally,	colchicine,	
despite	given	at	a	low	dose,	was	stopped	after	2	days	due	to	the	
patient	experiencing	nausea	and	persistent	diarrhea.	The	patient	
was	subsequently	placed	on	oral	prednisone	25	mg/day	with	
tapering;	his	serum	glucose	levels	were	tightly	controlled	after	
the	optimization	of	insulin	therapy.	
Intravenous	 (iv)	 alcalization	 therapy	 with	 bicarbonate	
was	added	to	raise	the	urinary	pH	and	reduce	the	size	of	the	
uric	acid	renal	calculi.	Once	the	serum	acid-base	balance	was	
re-established	and	the	fluid	challenge	restored,	serum	creatinine	
levels	improved.	The	patient	was	taken	off	the	ACE-I	and	placed	
instead	on	the	angiotensin	receptor	blocker	 losartan,	which	
has	been	shown	to	produce	a	uricosuric	effect.	Treatment	with	
uricase	(rasburicase),	an	enzyme	that	oxidizes	uric	acid	to	a	more	
soluble	form	and	indicated	for	the	treatment	of	hyperuricemia	
associated	with	tumor	lysis	syndrome,	was	introduced.	However,	
after	the	second	iv	administration,	the	patient	had	a	cutaneous	
allergic	reaction.	The	treatment	was	therefore	discontinued.	
It	was	hypothesized	that	rasburicase,	which	 is	a	nonhuman	
protein,	induced	an	allergic	reactions,	which	had	also	occurred	
when	the	patient	was	previously	given	allopurinol.
After	5	days	in	the	hospital,	the	patient	was	discharged	home.	
His	left	 lumbar	pain	was	significantly	reduced,	and	after	the	
expulsion	of	the	urinary	microcalculi,	ultrasound	showed	that	
the	hydronephrosis	was	significantly	improved.	The	pain	in	his	
hand	joints	was	mitigated	and	his	serum	creatinine	was	stable	
at	1.58	mg/dL.	His	serum	uric	acid	level	was	slightly	reduced	but	
was	still	greater	than	8	mg/dL.
5.3. Discussion
Evidence	 suggests	 that	 end-stage	 renal	 disorder	 (ESRD)	
is	characterized	by	a	state	of	chronic	inflammation	linked	to	
oxidative	stress,	endothelial	dysfunction,	vascular	calcification,	
and	wasting.	Reports	suggest	that	CKD	is	a	chronic	inflammatory	
disease,	as	it	is	now	recognized	that	rapid	kidney	function	loss	in	
CKD	is	independently	associated	with	increased	baseline	levels	of	
Table	2
Treatment	goals	in	gouty	arthritis
1 Terminate	attacks	
2 Provide	control	of	pain	and	inflammation	
3 Prevent	future	attacks	
4 Prevent	complications	such	as	tophi,	destructive	
arthropathy,	renal	stones,	and	renal	insufficiency
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CRP	and	soluble	tumor	necrosis	factor	receptor-2	[41].	Therefore,	
the	attenuation	of	the	inflammatory	response	to	renal	injury	on	
vascular	structures	induced	by	statin	therapy	may	explain	the	
renoprotective	actions	of	these	agents	in	patients	with	CKD	[42],	
and	suggests	that	inflammation	represents	an	important	target	
for	pathogenetic	interventions	both	in	AKI	and	the	progression	
of	CKD.
Recent	 evidence	 suggests	 that	 interleukin-1	 (IL-1),	 a	
proinflammatory	cytokine,	plays	a	major	role	 in	mediating	
gouty	 arthritis	 inflammation	 [6,24,43-46].	 Additionally,	
both	experimental	and	human	studies	show	that	the	NLRP3	
inflammasome	plays	a	role	in	the	development	of	acute	and	
chronic	tubulo-interstitial	disease	[47].	Moreover,	recent	data	
show	that	inflammasome	activation	is	related	to	proinflam-
matory	effects	of	NLRP3	 in	autologous	nephrotoxic	serum	
nephritis,	 including	NLRP3-mediated	glomerular	release	of	
pro-inflammatory	 cytokines	 [48].	 Therefore,	 therapeutic	
blockade	of	the	NLRP3/ASC/IL-1β	axis	may	also	be	beneficial	
in	glomerulonephritis	[49].
6.	 What	is	the	rationale	for	anti−IL-1β	therapy	
in	gouty	arthritis	and	other	chronic	diseases?
Acute	gouty	arthritis	appears	to	be	mediated	by	IL-1β	that	
exerts	 strong	 proinflammatory	 activities.	 In	 a	 randomized,	
controlled	trial,	canakinumab	–	a	fully	humanized	monoclonal	
anti-human	IL-1β	antibody	–	was	more	effective	in	reducing	
pain	and	risk	of	a	new	flare	in	patients	with	gouty	arthritis	as	
compared	with	triamcinolone	acetonide	[22].
Anti−IL-1β	therapy	is	an	alternative	for	patients	with	acute	
gouty	arthritis,	especially	when	NSAID	and	colchicine	therapy	
is	 contraindicated,	as	was	 the	case	 in	our	patient.	Of	note,	
canakinumab	has	no	significant	effect	on	renal	 impairment	
and	no	dose	adjustment	is	necessary	for	patients	with	renal	
impairment	[8].	Furthermore,	the	reduction	of	inflammation	
and	gouty	arthritis	with	anti−IL-lβ	 therapy	may	provide	an	
opportunity	to	increase	urate-lowering	therapy	to	an	optimal	
dose	 –	 another	 reason	 as	 to	 why	 treatment	 with	 an	 IL-1β	
inhibitor	may	benefit	our	patient.	
IL-1β	expression	has	also	been	observed	in	β-cells	of	patients	
with	type	2	diabetes,	suggesting	a	potential	role	of	IL-1	in	the	
pathogenesis	of	type	2	diabetes	via	increased	insulin	production,	
improved	insulin	sensitivity,	and	slowing	of	disease	progression	by	
increasing	β-cell	burden.	The	production	and	secretion	of	IL-1β	from	
β-cells	is	reported	to	be	induced	by	high	glucose	levels,	inhibiting	
the	function	and	promoting	the	apoptosis	of	β-cells	[50].	These	data	
may	provide	further	insight	into	the	cause	of	ESRD	in	patients	with	
type	2	diabetes	and	provide	a	fascinating	prospective	therapy	for	
patients	with	diabetes	mellitus,	the	most	common	cause	of	ESRD	
and	reason	for	requiring	dialysis	treatment	in	the	United	States.
IL-1β	inhibition	proved	successful	in	one	of	our	patients	who	
had	been	diagnosed	with	type	2	diabetes	and	Muckle-Wells	syn-
drome	(MWS),	a	rare	hereditary	autoinflammatory	disorder,	with	
accompanying	renal	amyloidosis	AA	and	renal	impairment.	We	
initiated	sc	anakinra	100	mg/day.	After	only	5	days	of	treatment,	
the	patient	had	significant	improvement	in	glycemic	control	and	
levels	of	the	inflammatory	marker	serum	amyloid	A	(SAA),	which	
decreased	from	4.5	mg/dL	to	0.5	mg/dL.	Additionally,	her	serum	
creatinine	level	decreased	from	4.5	mg/dL	to	3.8	mg/dL	and	the	
estimated	glomerular	filtation	rate	(GFR)	increased	from	10	mL/
min	to	13	mL/min	(personal	unpublished	data).	
We	recently	published	a	report	that	corroborated	the	benefits	
of	anti−IL-1β	therapy	in	renal	disease	associated	with	MWS.	Two	
patients,	father	and	son,	aged	52	and	26	years,	respectively,	with	
genetically-confirmed	MWS	with	amyloid	A	(AA)	deposits	on	
renal	biopsy,	received	canakinumab	every	60	days	over	a	period	
of	18	months.	Treatment	resolved	inflammatory	symptoms,	nor-
malized	SAA	levels,	and	markedly	improved	GFR	and	nephrotic	
proteinuria,	with	no	adverse	events.	These	data,	although	limited	
to	2	patients,	emphasize	 that	 therapeutic	 intervention	with	
canakinumab	suppresses	both	inflammation	and	IL-1β−mediated	
manifestations,	and	can	contribute	to	improved	kidney	function	
in	patients	with	MWS	who	have	overt	renal	amyloidosis,	with	
no	adverse	event	after	36	months	of	treatment	[51].
Despite	the	promising	clinical	results	achieved	with	anti−
IL-1β	therapy	in	patients	with	difficult-to-treat	gouty	arthritis,	
some	would	argue	that	the	costs	associated	with	this	therapy	is	
prohibitive.	However,	it	is	important	to	take	into	consideration	
the	overall	costs	involved	in	managing	acute	gout	attacks	and	the	
costs	for	repeated	hospitalizations	when	patients	are	managed	
unsuccessfully.
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